© Reuters. FILE PHOTO: CVS Health logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) -The U.S. Food and Drug Administration on Tuesday warned eight companies, including pharmacy giants CVS Health Corp (NYSE:) and Walgreens Boots Alliance (NASDAQ:), against manufacturing or marketing unapproved eye products.
The eye products addressed in the FDA's letters to these companies are illegally marketed to treat conditions like conjunctivitis, cataract and glaucoma, the agency said, adding that such drugs pose an increased risk to users as they can bypass some of the body's natural defenses.
Some of the these eye products were labeled to contain silver, the FDA said, adding that long-term use of drugs containing silver can cause some areas of the skin and other body tissues, including in the eye, to permanently turn gray or blue-gray.
CVS and Walgreens said they have stopped the sale of the unapproved eye drops, and that customers who purchased these products could return them for a full refund.
Among the companies, the FDA also pulled up Similasan, asking the privately held Swiss drugmaker to meet relevant safety limits for levels of diethylene glycol or ethylene glycol, two common contaminants in some medicine, as they could lead to lethal poisoning at higher levels.
Similasan did not immediately respond to Reuters' request for comment.
The U.S. health regulator has asked the companies to respond within 15 days of receipt of the letters and state how they will correct the violations.
The FDA warned that failure to correct the violations may result in legal action, including product seizure and court orders requiring the companies to stop manufacturing and distributing an unapproved product.
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.